Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 1,417 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluid administration Clear all

Conditions: Alcohol Withdrawal, Alcohol Abstinence, Alcohol Use Disorder
Interventions: Sodium Acetate, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Compartment Syndrome
Interventions: ECSPRESS catheter with active vacuum; Device
Lead sponsor: Twin Star Medical, Inc.; Industry
Eligibility: 18 Years to 44 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: High-risk Non-muscle Invasive Bladder Cancer
Interventions: Pembrolizumab, BCG; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2034
U.S. locations: 44
States / cities: Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 39 more

Conditions: Hematologic Malignancies
Interventions: Immune Globulin Infusion (Human), 10% Solution, Anti-CD19 CAR T Cells Preparation, Saline, Biospecimen Collection, Survey Administration, Electronic Health Record Review; Biological · Other · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 7
States / cities: Duarte, California • Miami, Florida • Tampa, Florida + 4 more

Conditions: Pain
Interventions: clonidine, adenosine, placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Not listed
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 2
States / cities: Winston-Salem, North Carolina

Conditions: HIV Infections
Interventions: raltegravir; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy
Interventions: Scopolamine + Donepezil Placebo + PF-04995274 Placebo, Scopolamine + Donepezil 5 mg + PF-04995274 Placebo, Scopolamine + Donepezil 10mg + PF-04995274 Placebo, Scopolamine + Donepezil Placebo + PF-04995274 0.25 mg, Scopolamine + Donepezil Placebo + PF-04995274 15 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Diabetic Ketoacidosis
Interventions: Early administration of subcutaneous insulin glargine dose, IV insulin infusion, IV fluid repletion; Other · Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 89 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Esophagoscopy Techniques, Colonoscopy
Interventions: EGD-assisted administration of colonoscopy prep, Control Group received standard prep by oral administration; Procedure
Lead sponsor: Rockford Gastroenterology Associates; Other
Eligibility: Not listed
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Rockford, Illinois

Conditions: Retinal Vein Occlusion, Macular Edema
Interventions: Ozurdex; Drug
Lead sponsor: Retina Macula Institute; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Torrance, California

Conditions: Infertility, Endometriosis
Interventions: PRP Experimental; Biological
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 23 Years to 45 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: HIV Infection
Interventions: Efavirenz; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 3 Years to 16 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 27
States / cities: Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 19 more

Conditions: Anemia, Sickle Cell
Interventions: Siplizumab, Exchange Transfusion, Total Body Irradiation, Stem Cell Infusion, Cyclophosphamide 50mg, Mesna, Sirolimus Oral Tablet, Rituximab or Biosimilar; Drug · Procedure
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Osteo Arthritis Knee
Interventions: Amniotic Fluid Injection, Standard of Care; Biological · Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Post-ERCP Acute Pancreatitis
Interventions: Indomethacin, Lactated Ringer's Solution, Normal Saline, Placebo; Drug
Lead sponsor: Cooper Norcross Health; Other
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: Chemotherapy-induced Neuropathic Pain, Chemotherapy-induced Peripheral Neuropathy
Interventions: Tetrodotoxin, Placebo; Drug
Lead sponsor: Wex Pharmaceuticals Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 15
States / cities: Santa Ana, California • Santa Rosa, California • Port Charlotte, Florida + 11 more

Conditions: Post-operative Voiding
Interventions: Urinary voiding assessment after midurethral sling; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 81 Years · Female only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Beachwood, Ohio • Mayfield Heights, Ohio

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Helminth ova; Biological
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 50 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Lymphoma, Acute Lymphoblastic Leukemia, Pediatric Cancer, Pediatric ALL, Pediatric Lymphoma
Interventions: Intravenous fluids; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 1 Year to 17 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Patellofemoral Pain Syndrome
Interventions: Intra-Articular Hyaluronic Acid-Euflexxa; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 40 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Surgical Wound, Wound Heal, Amputation
Interventions: PrevenaTM Device, Standard Dry Dressing; Device · Other
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Hydrocephalus, Normal Pressure
Interventions: Non-invasive measures; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 40 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Head Injury, Minor, Pediatric, Emergency Department Patient
Interventions: Hypertonic Saline ( 3% Sodium Chloride Saline), Normal Saline (0.9% NaCl); Other
Lead sponsor: University of Texas at Austin; Other
Eligibility: 8 Years to 17 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hyperemesis Gravidarum
Interventions: Metformin Extended Release Oral Tablet; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Birmingham, Alabama • Los Angeles, California

Search by objective public record fields.

Intravenous Acetate as an Adjunctive Treatment for Alcohol Withdrawal in Hospitalized Patients

Double Blinded, Randomized Clinical Trial of the Twin Star ECSPRESS Monitoring System for the Reduction of the Incidence of Fasciotomy

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

IVIG for Infection Prevention After CAR-T-Cell Therapy

Clonidine Versus Adenosine to Treat Neuropathic Pain

Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients

Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults

Early Subcutaneous Insulin Glargine Plus Standard of Care for Treatment of Diabetic Ketoacidosis

EGD-assisted Bowel Preparation for Colonoscopy

Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.

Platelet Rich Plasma Uterine Infusion

An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection

Siplizumab for Sickle Cell Disease Transplant

pAF for the Treatment of Osteoarthritis

Lactated Ringers With or Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis

A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain

Assessment of Voiding After Sling

Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis

Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia

Effectiveness Trial for Evaluating IAHA for PFPS

Evaluating the Outcomes for Incisional Application of Negative Pressure for Nontraumatic Amputations

A Study Comparing Shunt Placement Versus Endoscopic Third Ventriculostomy in the Treatment of Hydrocephalus

Hypertonic Saline for Mild TBI in Pediatric Patients

Hyperemesis Gravidarum Risk Reduction With Metformin